Drug Profile
Trastuzumab biosimilar - Celltrion
Alternative Names: CT-P06; CT-P6; HERZUMA; Herzuma; Trastuzumab BS “NK”Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Celltrion
- Developer Celltrion; Kern Pharma; Mundipharma International; Nippon Kayaku; Teva Pharmaceutical Industries
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 21 Apr 2023 Trastuzumab biosimilar is still active for HER2-positive breast cancer in Turkey
- 21 Apr 2023 Launched for Gastric cancer (Metastatic disease) in Turkey (IV)
- 21 Apr 2023 Launched for HER2-positive-breast-cancer (Combination therapy, Early-stage disease, Adjuvant therapy, Neoadjuvant therapy) in Turkey (IV)